The Role of Allogeneic Transplantation for Multiple Myeloma in Older Adults

2009 ◽  
pp. 127-142
Author(s):  
Heidi D. Klepin ◽  
David D. Hurd
Keyword(s):  
Older Adults ◽  
Multiple Myeloma ◽  
Allogeneic Transplantation

Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation

2005 ◽  
Vol 29 (8) ◽  
pp. 961-966 ◽  
Author(s):  
Sara Galimberti ◽  
Edoardo Benedetti ◽  
Fortunato Morabito ◽  
Federico Papineschi ◽  
Vincenzo Callea ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Minimal Residual Disease ◽  
Residual Disease ◽  
Allogeneic Transplantation ◽  
Prognostic Role ◽  
Minimal Residual

scholarly journals The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma

2018 ◽  
Vol 24 (7) ◽  
pp. 1392-1398 ◽  
Author(s):  
Koji Kawamura ◽  
Nobuhiro Tsukada ◽  
Yoshinobu Kanda ◽  
Takashi Ikeda ◽  
Akiyo Yoshida ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Japanese Society ◽  
Allogeneic Transplantation ◽  
Novel Agents

scholarly journals "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

2010 ◽  
Vol 2 (2) ◽  
pp. e2010013 ◽  
Author(s):  
Benedetto Bruno ◽  
Luisa Giaccone ◽  
Moreno Festuccia ◽  
Mario Boccadoro
Keyword(s):  
Multiple Myeloma ◽  
Standard Of Care ◽  
Allogeneic Transplantation ◽  
New Drugs ◽  
High Dose ◽  
Newly Diagnosed ◽  
Stem Cell Rescue ◽  
High Dose Melphalan ◽  
Anti Tumor Activity

High-dose melphalan with autologous stem cell rescue has been regarded as the standard of care for patients with newly diagnosed myeloma up to the age of 65-70 years. The recent development of agents with potent anti-tumor activity such as thalidomide, lenalidomide and bortezomib has further improved overall survival and response rates. However, relapse is a continuous risk.            Allografting is a potentially curative treatment for a subset of multiple myeloma patients for its well documented graft-vs-myeloma effects. However, its role has been hotly debated. Even though molecular remissions have been reported up to 50% after high-dose myeloablative conditionings, their applications, given the high toxicity, have been for long limited to younger relapsed/refractory patients. These limitations have greatly been reduced through the introduction of non-myeloablative/reduced-intensity conditionings.             The introduction of new drugs, characterised by low risks of early mortality, indeed requires to define role and timing of an allograft to capture the subset of patients who may most benefit from graft-vs-myeloma effects.   Ultimately, new drugs should not be viewed as mutually exclusive with an allograft. They may be employed to achieve profound cytoreduction before and enhance graft-versus-myeloma effects as consolidation/maintenance therapy after an allograft. However, this combination should be explored only in well-designed clinical trials.

Older Adults' Decline in Associative Memory: Assessing the Role of Speed of Processing and Attentional Resources

2008 ◽  
Author(s):  
Moshe Naveh-Benjamin ◽  
Susan Old ◽  
Yoko Hara ◽  
Jonathan Guez ◽  
Angela Kilb
Keyword(s):  
Older Adults ◽  
Associative Memory ◽  
Speed Of Processing ◽  
Attentional Resources

The role of nuclear factor-[kappa ]B in the biology and treatment of multiple myeloma

2001 ◽  
Vol 28 (6) ◽  
pp. 626-633 ◽  
Author(s):  
James R. Berenson ◽  
Hongjin M. Ma ◽  
Robert Vescio
Keyword(s):  
Multiple Myeloma ◽  
Nuclear Factor Kappa B ◽  
Nuclear Factor ◽  
Nuclear Factor Kappa

The Role of Dance to Improve Cognitive Function in the Older Adults: A Meta-Analytic Approach

2020 ◽  
Vol 59 (1) ◽  
pp. 267-275
Author(s):  
Yoongu Lee ◽  
Minseok Kwag ◽  
So-Mi Lee
Keyword(s):  
Older Adults ◽  
Cognitive Function ◽  
Analytic Approach
Sign in / Sign up

Export Citation Format

Share Document